Abstract
Aims
To develop a population pharmacokinetic model for simultaneous analysis of oral/intravenous cisplatin data in order to estimate the mean population pharmacokinetic parameters, mainly the bioavailability, of cisplatin and to evaluate the influence of covariates on the pharmacokinetic variability.
Methods
Pharmacokinetic and demographic data were collected from 32 adult patients (20 males/12 females, age range 47–76 years) receiving 30-min infusions or an oral formulation of cisplatin, 10–30 mg/m2, for various malignancies. Both total plasma and ultrafilterable or unbound platinum concentrations were determined.
Results
Unbound and total platinum concentrations were ascribed to a two-compartment model, with first-order absorption and elimination. The oral bioavailability (F) population estimates were, respectively, 0.39 and 0.30 with associated intersubject variabilities (ISV) of 24% and 26%. Peak concentrations following oral dosing occurred at 1.0 h and 1.6 h for unbound and total platinum, respectively. Clearance (CL) and central distribution volume (V 1) of unbound platinum were significantly related to body surface area (BSA). The CL and V 1 mean estimates were, respectively, 37 l/h and 23 l with an associated ISV of 15%. The final pharmacokinetic models were validated using 1000 bootstrap samples of the original datasets.
Conclusions
Both unbound and total platinum data allowed a fair evaluation of oral cisplatin disposition, with close estimations for both absorption rates and oral bioavailability. These results also support the conventional dose adjustment of cisplatin based on BSA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beal SL, Sheiner LB (1998) NONMEM user’s guide; NONMEM project group. University of California, San Francisco
Bonetti A, Franceschi T, Apostoli P, Messori A, Sperotto L, Cetto GL, Molino A, Leone R (1995) Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors. Ther Drug Monit 17:25
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31
Griffiths H, Shelley MD, Fish RG (1987) A modified pharmacokinetic model for platinum disposition in ovarian cancer patients receiving cisplatin. Eur J Clin Pharmacol 33:67
Hanada K, Nishijima K, Ogata H, Atagi S, Kawahara M (2001) Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum. Jpn J Clin Oncol 31:179
Ihaka R, Gentleman R (1996) R: a language for data analysis and graphics. J Comput Graph Stat 5:299
Korst AE, van der Sterre ML, Gall HE, Fichtinger-Schepman AM, Vermorken JB, van der Vijgh WJ (1998) Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res 4:331
Le Roy AF, Wehling ML, Sponseller HL (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18:184
Murase M, Kondo K, Kodera Y, Kiriyama K, Akiyama S, Ito K, Yokoyama Y, Shirasaka T, Takagi H (1993) The clinical effect of chemotherapy with 5-FU and low-dose CDDP in patients with advanced gastric cancer. Jpn J Cancer Chemother 21:1025
Nagai N, Ogata H, Wada Y, Tsujino D, Someya K, Ohno T, Masuhara K, Tanaka Y, Takahashi H, Nagai H, Kato K, Koshiba Y, Igarashi T, Yokoyama A, Kinameri K, Kato T, Kurita Y (1998) Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J Clin Pharmacol 38:1025
Parke J, Holford N, Charles B (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 59:19
Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A (1994) Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups. Lung Cancer 10:S263
Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, van Groeningen CJ, Hart GA, Pinedo HM (1986) Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 39(2):136–144
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Urien, S., Brain, E., Bugat, R. et al. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol 55, 55–60 (2005). https://doi.org/10.1007/s00280-004-0852-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-004-0852-8